18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Male Breast Cancer|Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adult Brain Tumor|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Colon Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Hypopharyngeal Cancer|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Laryngeal Cancer|Recurrent Lip and Oral Cavity Cancer|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Nasopharyngeal Cancer|Recurrent Non-small Cell Lung Cancer|Recurrent Oropharyngeal Cancer|Recurrent Pancreatic Cancer|Recurrent Paranasal Sinus and Nasal Cavity Cancer|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Stage IIIA Breast Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Breast Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Stage IV Non-small Cell Lung Cancer|Stage IV Pancreatic Cancer|Stage IV Renal Cell Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVA Salivary Gland Cancer|Stage IVB Colon Cancer|Stage IVB Salivary Gland Cancer|Stage IVC Salivary Gland Cancer|Tongue Cancer|Unspecified Adult Solid Tumor, Protocol Specific
Interventions: DRUG: 18F-fludeoxyglucose (18F-FDG)|DRUG: 18F-FPPRGD2
Sponsor: Sanjiv Sam Gambhir
Collaborators: National Cancer Institute (NCI)